Felix Wermelinger

899 total citations · 1 hit paper
8 papers, 608 citations indexed

About

Felix Wermelinger is a scholar working on Rheumatology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Felix Wermelinger has authored 8 papers receiving a total of 608 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Rheumatology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Genetics. Recurrent topics in Felix Wermelinger's work include Vasculitis and related conditions (3 papers), Otitis Media and Relapsing Polychondritis (2 papers) and Systemic Lupus Erythematosus Research (2 papers). Felix Wermelinger is often cited by papers focused on Vasculitis and related conditions (3 papers), Otitis Media and Relapsing Polychondritis (2 papers) and Systemic Lupus Erythematosus Research (2 papers). Felix Wermelinger collaborates with scholars based in Switzerland and Austria. Felix Wermelinger's co-authors include Sabine Adler, Stephan Reichenbach, Peter M. Villiger, Michael Seitz, Stefan Kuchen, Diana Dan, Lukas Bütikofer, PM Villiger, Harald Bonél and Michael Fricker and has published in prestigious journals such as The Lancet, Swiss Medical Weekly and Rheumatology International.

In The Last Decade

Felix Wermelinger

7 papers receiving 586 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial

2016 377 citations Peter M. Villiger, Sabine Adler et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Felix Wermelinger Switzerland	5	459	423	175	100	75	8	608
G. Bonilla Spain	4	206 0.4×	294 0.7×	142 0.8×	135 1.4×	25 0.3×	10	436
Alessandra Ghinoi Italy	11	332 0.7×	276 0.7×	109 0.6×	61 0.6×	44 0.6×	18	485
Josep Angel Bosch-Gil Spain	12	276 0.6×	230 0.5×	78 0.4×	106 1.1×	39 0.5×	14	546
Lauren K. Young United States	4	741 1.6×	325 0.8×	205 1.2×	155 1.6×	146 1.9×	4	805
Luigi Macchioni Italy	9	283 0.6×	371 0.9×	139 0.8×	89 0.9×	11 0.1×	12	511
Sven Weidner Germany	7	335 0.7×	124 0.3×	98 0.6×	109 1.1×	104 1.4×	9	445
Alicia Rodríguez-Pla United States	10	261 0.6×	159 0.4×	36 0.2×	122 1.2×	27 0.4×	27	387
Ayumi Okuyama Japan	11	113 0.2×	206 0.5×	100 0.6×	91 0.9×	45 0.6×	23	445
Elisabeth A. Berg United States	7	474 1.0×	187 0.4×	115 0.7×	289 2.9×	104 1.4×	9	604
Daina Selga Sweden	12	386 0.8×	134 0.3×	136 0.8×	106 1.1×	134 1.8×	18	458

Countries citing papers authored by Felix Wermelinger

Since Specialization

Citations

This map shows the geographic impact of Felix Wermelinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Felix Wermelinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Felix Wermelinger more than expected).

Fields of papers citing papers by Felix Wermelinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Felix Wermelinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Felix Wermelinger. The network helps show where Felix Wermelinger may publish in the future.

Co-authorship network of co-authors of Felix Wermelinger

This figure shows the co-authorship network connecting the top 25 collaborators of Felix Wermelinger. A scholar is included among the top collaborators of Felix Wermelinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Felix Wermelinger. Felix Wermelinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Adler, Sabine, et al.. (2017). Diagnostic value of contrast-enhanced magnetic resonance angiography in large-vessel vasculitis. Swiss Medical Weekly. 147(708). w14397–w14397. 23 indexed citations

2.

Villiger, Peter M., Sabine Adler, Stefan Kuchen, et al.. (2016). Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet. 387(10031). 1921–1927. 377 indexed citations breakdown →

3.

Reichenbach, Stephan, et al.. (2011). Rapid induction of remission in large vessel vasculitis by IL-6 blockade. Swiss Medical Weekly. 141(304). w13156–w13156. 137 indexed citations

4.

Finckh, Axel, Jean Dudler, Felix Wermelinger, et al.. (2010). Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine. 77(4). 313–318. 31 indexed citations

5.

Jandus, Peter, Wei Wang, Michael Seitz, Felix Wermelinger, & Hans-Peter Köhler. (2010). High Serum Ferritin in Adult-Onset Still's Disease. International Journal of Clinical Medicine. 1(2). 81–83.

6.

Wermelinger, Felix, et al.. (2010). Kreuzschmerz: Wann ist eine bildgebende Abklärung sinnvoll?. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. 10(9). 1 indexed citations

7.

Finckh, Axel, Jean Dudler, Felix Wermelinger, et al.. (2010). Influence des anticorps anti-infliximab et des concentrations résiduelles d’infliximab sur l’apparition d’une résistance acquise à l’infliximab chez les patients atteints de polyarthrite rhumatoïde. Revue du Rhumatisme. 77(6). 602–608. 1 indexed citations

8.

Fricker, Michael, Andreas Baumann, Felix Wermelinger, PM Villiger, & Arthur Helbling. (2006). A novel therapeutic option in Cogan diseases? TNF-α blockers. Rheumatology International. 27(5). 493–495. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact